EasyM

04/29/2026

The "Baseline" Sample: Don’t Miss the Window for MRD Tracking

If you are considering advanced minimal residual disease (MRD) monitoring for Multiple Myeloma, there is a critical first step for many technologies: The Baseline.

Why it’s essential:

Newer monitoring technologies work by identifying your cancer’s unique molecular "fingerprint." To track this fingerprint at ultra-sensitive levels later, the lab must first "map" it while your levels are still detectable (usually at diagnosis or before a new treatment).

Share this to your networks to help others learn about the importance of baselines 💡

04/22/2026

In case you missed it last week 📰

The University of Waterloo recently published a news article on the development of EasyM, a blood based minimal residual disease (MRD) test for Multiple Myeloma (MM) 🩸

Key Takeaway Points:

- Sensitivity & Specificity: Research indicates that EasyM can detect the unique M-protein "fingerprint" even when traditional methods cannot.

- Observation Windows: In clinical evaluations, blood-based monitoring identified rising M-protein levels up to 11 months earlier than conventional methods.

- Accessibility: Following the Ministry of Health provisional license, this non-invasive MRD monitoring tool is available for clinical use in Canada.

Read the full article here: https://uwaterloo.ca/news/diagnosing-cancer-drop-blood

04/21/2026

What a week last week!

As part of our National Medical Laboratory Week celebrations, we were thrilled to host our partners from Evosep, Promega, and Thermo Fisher Scientific for a series of impactful Lunch & Learns last week.

Key takeaways from the week:

Patient-Centered Care: Understanding how lab precision directly impacts patient outcomes.
Companion Diagnostics: Exploring the future of personalized medicine and targeted therapy.
Best Practices: Deep dives into clinical lab quality to ensure reliability.

A huge thank you to our guest speakers for sharing their expertise and helping us sharpen our focus on the patients we serve.

04/17/2026

We’re proud to see our work featured by the University of Waterloo 🧡

A recent article highlights how EasyM is helping transform multiple myeloma care, making it possible to detect and monitor cancer with a simple blood test instead of invasive bone marrow biopsies.

Our technology uses each patient’s unique M-protein “fingerprint” to track disease progression and can detect relapse 2 to 11 months earlier than traditional methods.

This recognition reflects more than a decade of research, collaboration, and a shared goal: improving patient care through innovation.

The article also highlights that EasyM is available for Canadian patients through a provisional licence from the Ontario Ministry of Health.

Read the full story here: https://lnkd.in/evvmNZai

Advances in medical research are reshaping how blood cancers are diagnosed and monitored.

Rapid Novor, a Waterloo‑based company co‑founded by University of Waterloo professor Dr. Bin Ma, is helping transform care for myeloma, a blood cancer affecting the bone marrow. Traditionally, patients undergo repeated and invasive bone marrow biopsies to diagnose the disease and monitor treatment.

Rapid Novor’s EasyM test offers a non‑invasive alternative. Using a simple blood draw, this highly sensitive test detects and measures M‑protein, a key myeloma biomarker, providing clinicians with a safer and more accessible option for ongoing disease monitoring.

More: https://uwaterloo.ca/news/diagnosing-cancer-drop-blood |

04/13/2026

Celebrating the experts behind the answers 🔬✨

It’s National Medical Laboratory Week, and we are incredibly proud to celebrate our medical laboratory staff who are the "engine room" of EasyM.

We have a fun-filled week of activities planned to celebrate our incredible team and the vital work they do for Multiple Myeloma patients.

👀 Keep an eye on our feed all week for updates!

To all the lab tech superstars, pathologists, and scientists: Thank you for your precision, your passion, and your persistence. Happy !

04/10/2026

One day. One goal: Advancing the future of MRD 💪

We will be on the ground tomorrow in Miami for the myeloma MRD meeting! With a packed schedule, it’s going to be a milestone day for the community.

At EasyM, we are passionate about making MRD monitoring more accessible and patient-friendly through blood-based clonotypic mass spectrometry.

📩 DM us to set up a quick chat, we’d love to talk all things MRD with you!

04/09/2026

Major Milestone Announcement 📢

First Canadian prospective clinical study evaluating EasyM® for minimal residual disease (MRD) monitoring in multiple myeloma has completed patient enrollment.

Conducted in collaboration with Princess Margaret Cancer Centre (PMCC), this study explores a non-invasive, blood-based approach to tracking disease response in patients with newly diagnosed multiple myeloma (NDMM). By reducing reliance on bone marrow biopsies, EasyM® has the potential to make MRD testing more accessible, more frequent, and more patient-friendly, while maintaining high sensitivity and specificity.

MRD status is one of the strongest predictors of patient outcomes, and innovations like EasyM® could help enable more personalized, responsive treatment strategies, where therapy is adjusted based on more frequent disease monitoring.

We are deeply grateful to the patients, clinicians, and partners who made this milestone possible. Your participation and dedication are helping shape the future of multiple myeloma care.

Read the full announcement here: https://easym.com/rapid-novor-easym-multiple-myeloma-study-enrollment-complete/

04/02/2026

💡Non-secretory and oligosecretory multiple myeloma (MM) are often harder to detect, but they’re not identical:

Non-Secretory:
- Plasma cells don’t produce detectable M-protein at all
- Standard blood or urine tests may show nothing
- Monitoring relies on bone marrow biopsies & imaging

Oligosecretory:
- Plasma cells produce very low levels of M-protein
- Standard tests may miss it, even though disease is active
- Advanced tests like mass spectrometry can reveal hidden disease

Read more here: https://www.easym.com/types-of-multiple-myeloma/

03/31/2026

💡Did you know?

Not all multiple myeloma produces a complete M-protein.

In light chain only myeloma, malignant plasma cells produce only part of the antibody, called free light chains (kappa or lambda), instead of the full M-protein.

What makes it different?

- No intact (whole) M-protein
- Free light chains circulate rapidly and are cleared by the kidneys
- Standard monitoring can be more challenging

These free light chains can build up and cause kidney damage, making accurate detection critical.

Advanced mass spectrometry methods can detect and monitor light chain only disease, providing a sensitive, non-invasive way to track disease - even when traditional methods fall short.

Read more here: https://www.easym.com/types-of-multiple-myeloma/

03/19/2026

🚨 Early Detection in Multiple Myeloma After CAR-T Therapy!

A new study lead by Dr. Pasvolsky and colleagues at UT MD Anderson Cancer Center shows that EasyM, a blood-based clonotypic mass spectrometry-based assay, can track minimal residual disease (MRD) in multiple myeloma patients receiving Ciltacabtagene Autoleucel (cilta-cel) with unprecedented sensitivity.

Key Finding: EasyM spotted relapse 249 days before clinical progression, while traditional SPEP tests were still negative. This could help clinicians intervene earlier and tailor post-CAR-T monitoring.

This is the first study using EasyM in the post-CAR-T setting, and the results are promising for improving disease surveillance.

Read the full abstract: https://www.easym.com/mrd-monitoring-by-easym-in-multiple-myeloma-patients-receiving-ciltacabtagene-autoleucel/

03/16/2026

🩸 Who is at higher risk for multiple myeloma?

• Adults over 60
• Individuals of African Ancestry
• Men (slightly higher risk than women)
• People with a family history of blood cancers
• Those diagnosed with MGUS (a precursor condition)

Understanding these risk factors helps us advocate for earlier testing and monitoring, because knowledge is power. 💪

03/10/2026

🚨 Important news for Canadians living with multiple myeloma 🚨

For the first time, minimal residual disease (MRD) testing for multiple myeloma can be offered in Canada by a Canadian company for Canadian patients.

Rapid Novor’s EasyM® MRD blood test has received a provisional license from the Ontario Ministry of Health, allowing doctors to monitor the disease using a simple blood draw instead of repeated bone marrow biopsies.

Why this is important for patients:
• No painful bone marrow procedures
• Allows more frequent monitoring of the disease
• Can detect disease outside the bone marrow
• Easier testing logistics and more collection sites
• Better access for patients in rural and underserved communities

This is an important step toward improving how multiple myeloma is monitored across Canada.

🔗 Read the full announcement: https://www.easym.com/rapid-novors-blood-test-for-multiple-myeloma-mrd-monitoring-receives-moh-provisional-license/